We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current SLRN market cap is 440.93M. The company's latest EPS is USD -3.8040 and P/E is -1.14.
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -179.83M | -42.7M | -94.42M | -105.11M | -82.77M |
Net Income | -176.45M | -26.04M | -83.94M | -95.21M | -34.97M |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 |
Operating Income | -69.18M | -422.06M |
Net Income | -64.77M | -381.64M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Total Assets | 298.52M | 835.13M | 800.49M | 742.69M | 697.48M |
Total Liabilities | 45.28M | 34.06M | 68.11M | 86.35M | 53.42M |
Total Equity | -143.35M | 801.07M | 732.38M | 656.34M | 644.07M |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Assets | 319.92M | 742.69M |
Total Liabilities | 26.19M | 86.35M |
Total Equity | -102.86M | 656.34M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Operating | -25.33M | -56.95M | -96.07M | -169.71M | -57.3M |
Investing | 47.54M | -220.33M | -355.14M | -447.74M | 100.9M |
Financing | -129k | 566.34M | 565.84M | 568.44M | 2.81M |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Operating | -61.52M | -169.71M |
Investing | -47.87M | -447.74M |
Financing | 274.26M | 568.44M |
Market Cap | 440.93M |
Price to Earnings Ratio | -1.14 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 1.99 |
Price to Book Ratio | 0.66 |
Dividend Yield | - |
Shares Outstanding | 100.33M |
Average Volume (1 week) | 650.44k |
Average Volume (1 Month) | 469.15k |
52 Week Change | -50.23% |
52 Week High | 9.00 |
52 Week Low | 3.36 |
Spread (Intraday) | 0.05 (1.13%) |
Company Name | ACELYRIN Inc |
Address |
1209 orange st wilmington, delaware 19801 |
Website | https://www.acelyrin.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions